

## DAFTAR PUSTAKA

- Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A. COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System. *World Neurosurg.* 2020;140:49-53. doi:10.1016/j.wneu.2020.05.193
- Agosti E, Giorgianni A, D'Amore F, Vinacci G, Balbi S, Locatelli D. Is Guillain-Barré syndrome triggered by SARS-CoV-2? Case report and literature review. *Neurol Sci.* 2021 ;42(2):607-612. doi: 10.1007/s10072-020-04553-9. Epub 2020 Jul 9. PMID: 32643136; PMCID: PMC7343406.
- Alberti P, Beretta S, Piatti M, Karantzoulis A, Piatti ML, Santoro P, Viganò M, Giovannelli G, Pirro F, Montisano DA, Appollonio I, Ferrarese C. Guillain-Barré syndrome related to COVID-19 infection. *Neurol Neuroimmunol Neuroinflamm.* 2020 ;7(4):e741. doi: 10.1212/NXI.0000000000000741. PMID: 32350026; PMCID: PMC7217652.
- Ansari B, Basiri K, Derakhshan Y, Kadkhodaei F, Okhovat AA. Epidemiology and Clinical Features of Guillain-Barre Syndrome in Isfahan, Iran. *Adv Biomed Res.* 2018;7:87. \. doi:10.4103/abr.abr\_50\_17
- Bigaut K, Mallaret M, Baloglu S, Nemoz B, Morand P, Baicry F, Godon A, Voulleminot P, Kremer L, Chanson JB, de Seze J. Guillain-Barré syndrome related to SARS-CoV-2 infection. *Neurol Neuroimmunol Neuroinflamm.* 2020 ;7(5):e785. doi: 10.1212/NXI.0000000000000785. Erratum in: *Neurol Neuroimmunol Neuroinflamm.* 2020 Jul 9;7(5): PMID: 32461235; PMCID: PMC7286648.
- Bölükbaşı F, Ersen G, Gündüz A, Karaali-Savrun F, Yazici S, Uzun N, Akalin M A, & Kiziltan ME. Guillain-Barré Syndrome and Its Variants: Clinical Course and Prognostic Factors. *Noro psikiyatri arsivi,* 2019: 56(1), 71–74. <https://doi.org/10.5152/npa.2017.18091>
- Burns T. Guillain-Barré Syndrome. *Seminars in Neurology,* 2008: 28(2), 152–167. doi:10.1055/s-2008-1062261
- Civardi C, Collini A, Geda DJ, Geda C. Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection. *Journal of Neurology, Neurosurgery & Psychiatry,* 2020;91:1361-1362.
- Coen M, Jeanson G, Culebras Almeida LA, Hübers A, Stierlin F, Najjar I, Ongaro M, Moulin K, Makrygianni M, Leemann B, Kronig I, Bertrand J, Reny JL, Schibler M, Serratrice J. Guillain-Barré syndrome as a complication of SARS-CoV-2

- infection. *Brain Behav Immun*. 2020 ;87:111-112. doi: 10.1016/j.bbi.2020.04.074. Epub 2020 Apr 28. PMID: 32360440; PMCID: PMC7194931.
- Cutillo G, Saariaho AH, Meri S. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. *Cell Mol Immunol*, 2020: **17**, 313–322. <https://doi.org/10.1038/s41423-020-0388-9>
- Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. *Neurol Clin*. 2013;31(2):491-510. doi:10.1016/j.ncl.2013.01.005
- Donofrio PD. Gullain-Barré Syndrome. *CONTINUUM: Lifelong Learning in Neurology*. 2017: 23(5), 1295-1309. Doi: 10.1212/com.0000000000000513
- Fadaka AO, Sibuyi NRS, Adewale OB, et al. Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. *J Int Med Res*. 2020;48(8):300060520949077. doi:10.1177/0300060520949077
- Garg M. Respiratory Involvement in Guillain-Barre Syndrome: The Uncharted Road to Recovery. *J Neurosci Rural Pract*. 2017;8(3):325-326. doi:10.4103/jnrp.jnrp\_96\_17R1
- Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. *Trends Immunol*. 2020;41(12):1100-1115. doi:10.1016/j.it.2020.10.004
- Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol*. 2021;19(3):141-154. doi:10.1038/s41579-020-00459-7
- Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. *Environ Res*. 2020;188:109819. doi:10.1016/j.envres.2020.109819
- Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. *Viruses*. 2020;12(4):372. Published 2020 Mar 27. doi:10.3390/v12040372
- Kaida K, Ariga T, Yu RK. Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders--a review. *Glycobiology*. 2009;19(7):676-692. doi:10.1093/glycob/cwp027
- Kaida K. Gullain-Barré Syndrome. *Myelin*. 2019: 323-331. Doi: 10.1007/978-981-32-9636-7\_20
- Krishnan A, Hamilton JP, Alqahtani SA, Woreta TA. COVID-19: An overview and a clinical update. *World J Clin Cases*. 2021;9(1):8-23. doi:10.12998/wjcc.v9.i1.8

- Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. *Nat Rev Neurol*. 2019;15(11):671-683. doi:10.1038/s41582-019-0250-9
- Malek E & Salameh J. Guillain-Barré Syndrome. *Seminars in Neurology*. 2019; 29(05), 589-595. Doi: 10.1055/s-0039-1693005
- McGrogan A, Madle GC, Seaman HE, de Vries CS. The Epidemiology of Guillain-Barré Syndrome Worldwide. *Neuroepidemiology*. 2008; 32(2), 150–163. doi:10.1159/000184748
- Nguyen TP, Taylor RS. Guillain Barre Syndrome. [Updated 2020 Nov 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK532254/>
- Orlikowski D, Prigent H, Sharshar T, Lofaso F, Raphael JC. Respiratory dysfunction in guillain-barré syndrome. *Neurocrit Care* 2004 : 1, 415–422. <https://doi.org/10.1385/NCC:1:4:415>
- Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: A systematic review and meta-analysis. *Eur J Neurol*. 2021;28(10):3517-3529. doi:10.1111/ene.14860
- Papri N, Islam Z, Leonhard SE, Mohammad QD, Endzt HP, Jacobs BC. Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects. *Nat Rev Neurol* 2021; 17, 285–296. <https://doi.org/10.1038/s41582-021-00467-y>
- Saeed ML, Kaleem Baloch B, Mahmud SN, et al. Role of Anti-ganglioside Antibodies in the Diagnosis of Guillain-Barré Syndrome as an Alternate Investigation. *Cureus*. 2019;11(5):e4625. Published 2019 May 9. doi:10.7759/cureus.4625
- Sancho-Saldaña A, Lambea-Gil Á, Liesa JLC, Caballo MRB, Garay MH, Celada DR, Serrano-Ponz M. Guillain-Barré syndrome associated with leptomenigeal enhancement following SARS-CoV-2 infection. *Clinical Medicine (London, England)*. 2020 ;20(4):e93-e94. doi: 10.7861/clinmed.2020-0213. Epub 2020 Jun 9. PMID: 32518103; PMCID: PMC7385766.
- Sriwastava S, Kataria S, Tandon M, et al. Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series. *J Neurol Sci*. 2021;420:117263. doi:10.1016/j.jns.2020.117263
- Su XW, Palka SV, Rao RR, Chen FS, Brackney CR, Cambi F. SARS-CoV-2-associated Guillain-Barré syndrome with dysautonomia. *Muscle Nerve*. 2020 ;62(2):E48-E49. doi: 10.1002/mus.26988. Epub 2020 Jun 1. PMID: 32445201; PMCID: PMC7283744.

- Tan C, Razali SNO, Goh K, Shahrizaila N. The utility of Guillain-Barré syndrome prognostic models in Malaysian patients. *Journal of the Peripheral Nervous System*. 2019. doi:10.1111/jns.12320
- Tekin AB, Zanapalioglu U, Gulmez S, Akarsu I, Yassa M, Tug N. Guillain Barre Syndrome following delivery in a pregnant woman infected with SARS-CoV-2. *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*. 2021 Apr;86:190-192. doi: 10.1016/j.jocn.2021.01.028. Epub 2021 Feb 2. PMID: 33775326; PMCID: PMC7993757.
- Tian J, Cao C, Li T, Zhang K, Li P, Liu Y, Liu X. Electrophysiological Subtypes and Prognostic Factors of Guillain-Barre Syndrome in Northern China. *Front Neurol*. 2019;10:714. doi: 10.3389/fneur.2019.00714. PMID: 31333568; PMCID: PMC6614537.
- Tiet MY, AlShaikh N. Guillain-Barré syndrome associated with COVID-19 infection: a case from the UK. *BMJ Case Reports*. 2020 Jul 8;13(7):e236536. doi: 10.1136/bcr-2020-236536. PMID: 32641309; PMCID: PMC7348325.
- Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, Franciotta D, Baldanti F, Daturi R, Postorino P, Cavallini A, Micieli G. Guillain-Barré Syndrome Associated with SARS-CoV-2. *N Engl J Med*. 2020 ; 382(26):2574-2576. doi: 10.1056/NEJMc2009191. Epub 2020 Apr 17. PMID: 32302082; PMCID: PMC7182017.
- Umakanthan S, Sahu P, Ranade AV, et al. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). *Postgrad Med J*. 2020;96(1142):753-758. doi:10.1136/postgradmedj-2020-138234
- Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. *Front Cell Infect Microbiol*. 2020;10:587269. Published 2020 Nov 25. doi:10.3389/fcimb.2020.587269
- Webb S, Wallace VC, Martin-Lopez D, Yogarajah M. Guillain-Barré syndrome following COVID-19: a newly emerging post-infectious complication. *BMJ Case Reports*. 2020;13(6):e236182. doi: 10.1136/bcr-2020-236182. PMID: 32540883; PMCID: PMC7298664.
- Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *Lancet*. 2016;388(10045):717-727. doi:10.1016/S0140-6736(16)00339-1
- Yamagishi Y, Kuwahara M, Suzuki H, Sonoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida K, Mutoh T, Tamasaki R, Takashima H, Matsui M, Nishiyama K, Sobue G, Kusunoki S. Serum IgG anti-GD1a antibody and

mEGOS predict outcome in Guillain-Barré syndrome. *Journal of Neurology, Neurosurgery & Psychiatry* 2020;91:1339-1342.

Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis -A review of current methods. *Biosens Bioelectron.* 2021;172:112752. doi:10.1016/j.bios.2020.112752

Zaeem, Z., Siddiqi, Z. & Zochodne, D.W. Autonomic involvement in Guillain-Barré syndrome: an update. *Clin Auton Res* 2019 : 29, 289–299. <https://doi.org/10.1007/s10286-018-0542-y>

Zhang Y, Zhao Y, Wang Y. Prognostic factors of Guillain-Barré syndrome: a 111-case retrospective review. *Chin Neurosurg J.* 2018;4:14. doi:10.1186/s41016-018-0122-y